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  75 
Key points 76 
Question Is total laparoscopic hysterectomy equivalent to abdominal hysterectomy for early stage 77 
endometrial cancer surgery treatment?    78 
Findings In this clinical trial of 760 women with stage I endometrial cancer, disease-free survival at 79 
4.5 years was 81.6% with total laparoscopic hysterectomy compared to 81.3% with total abdominal 80 
hysterectomy (difference 0.3% (favouring TLH), 95%CI, -5.53% to 6.13%) meeting pre-specified 81 
criteria for equivalence. 82 
Meaning In this trial of women with early stage endometrial cancer, disease-free survival was 83 
equivalent following total laparoscopic hysterectomy compared with total abdominal hysterectomy. 84 
New and proposed better surgical methods of treating early stage endometrial cancer should be 85 
tested against total laparoscopic hysterectomy in the future. 86 
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Abstract  87 
IMPORTANCE Current standard treatment for endometrial cancer involves removal of uterus, 88 
adnexa ± lymph nodes. Few randomized trials have compared disease-free survival outcomes for 89 
surgical approaches.   90 
OBJECTIVE To investigate whether total laparoscopic hysterectomy (TLH) is equivalent to total 91 
abdominal hysterectomy (TAH) in women with treatment-naive endometrial cancer. 92 
DESIGN, SETTING, AND PARTICIPANTS  Multinational, randomized equivalence trial 93 
evaluating the laparoscopic approach to endometrial cancer (LACE). Between October 7, 2005 and 94 
June 30, 2010, 27 surgeons from 20 tertiary gynaecological cancer centres in Australia, New 95 
Zealand, and Hong Kong randomised 760 women with stage I endometrioid endometrial cancer to 96 
either TLH or TAH. Follow-up ended 3
rd
 March 2016.  97 
INTERVENTIONS  353 patients were randomized to TAH, 407 to TLH.  98 
MAIN OUTCOMES AND MEASURES  Analysis according to intention-to-treat assessed the 99 
primary outcome of disease-free survival (DFS, time interval between surgery and date of first 100 
recurrence including any new localized or distant endometrial cancer recurrence or any new 101 
cancers, at 4.5 years post-randomization). The pre-specified equivalence boundary was ∆=±7%.  102 
Among seven pre-specified secondary outcomes, disease recurrence and overall survival are 103 
reported.   104 
RESULTS Patients were followed for a median of 4.5 years. Of 760 patients who were randomized 105 
(mean age 63 years), 679 (89%) completed the trial. At 4.5 years follow-up, DFS was 81.3% in the 106 
TAH and 81.6% in the TLH group. Equivalence was established with a DFS rate difference of 0.3% 107 
(favoring TLH) [95% CI: -5.53% to 6.13], p for equivalence =0.007. There was no statistical 108 
difference in endometrial cancer recurrences between the two groups (TAH 28 of 353 (7.9%) and 109 
TLH 33 of 407 (8.1%), risk difference 0.2%, 95% CI: -3.7 to 4.0%, p=0.93) or in overall survival 110 
(TAH 24 of 353 (6.8%) and TLH 30 of 407 (7.4%), risk difference 0.6%, 95% CI: -3.0 to 4.2%, 111 
p=0.76).  112 
 113 
CONCLUSIONS AND RELEVANCE Among women with stage I endometrioid endometrial 114 
cancer, the use of TAH compared with TLH resulted in equivalent DFS at 4.5 years and no 115 
difference in overall survival was observed. These findings support the use of laparoscopic 116 
hysterectomy for stage 1 endometrial cancer.  117 
 118 
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Endometrial cancer is the most common gynaecological cancer in developed countries.1 Obese, 129 
nulliparous and women with Lynch syndrome are at risk.
2
 Treatment is mainly surgical and 130 
includes a total hysterectomy and bilateral salpingo-oophorectomy.
3
 Surgical staging, to determine 131 
the extent of disease, is controversial. Postoperative treatment is tailored to histopathological risk 132 
factors and disease stage.
3, 4
  133 
At the start of the laparoscopic approach to endometrial cancer (LACE) trial in 2005, few patients 134 
were offered a laparoscopic hysterectomy (LH). At the time concerns included that it could pose 135 
greater risks in obese patients, have a higher risk of intraoperative injuries, inferior disease-specific 136 
survival, or port-site metastases.
5
 Subsequent data by three large randomized trials suggested that 137 
total LH may be equally safe as total abdominal hysterectomy (TAH)
6
 and have short-term 138 
advantages including less pain, better quality of life (QoL),
7-9
 decreased risk of surgical adverse 139 
events,
10
 and economic savings.
11
 A Cochrane review and meta-analysis summarized the wider 140 
literature.
12
 141 
These now well-characterized short-term advantages have supported the global trend to adopt LH 142 
despite little data to confirm its efficacy in regard to disease-free and overall survival.
13, 14
 A meta-143 
analysis 
12
 found only three small  (each had n<160) and one large trial  (n=2,616) formally 144 
evaluating survival endpoints. These trials are heterogeneous with respect to their LH technique; 145 
just two trials  focused on patients with stage 1 endometrial cancer, and only one trial used a total 146 
LH, while the other three trials allowed laparoscopic-assisted vaginal hysterectomy.  147 
The primary hypothesis of the present trial was that Total Laparoscopic Hysterectomy (TLH) is 148 
associated with equivalent disease-free survival (DFS) when compared to the standard treatment of 149 
TAH for women with apparent Stage I endometrial cancer.  150 
 151 
152 
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Methods  153 
Study design and Procedures 154 
This multinational, randomized, phase 3, equivalence trial compared TAH ± lymphadenectomy to 155 
TLH ± lymphadenectomy in women with apparent stage 1 endometrial cancer (EC).  Between 156 
October 7, 2005 and June 30, 2010, patients were recruited through one of 20 participating tertiary 157 
gynaecological cancer centres in Australia, New Zealand, and Hong Kong. Recruiting centres came 158 
on board as site specific ethics approval was obtained. They differed greatly in size and commonly 159 
recruited 0-10 patients/month. Ethics approval was obtained from each hospital’s Human Research 160 
and Ethics Committees.  161 
The full trial protocol and statistical analysis plan are included in the online supplement. The trial’s 162 
design and methods were described in 2006.
15
 The rationale for an equivalence trial was based on 163 
retrospective studies which showed promising morbidity and survival results.  164 
 165 
Written informed consent was obtained from patients prior to randomization. Eligibility and 166 
exclusion criteria were described in detail previously.
15
 In brief, the trial enrolled patients with 167 
histologically confirmed endometrioid adenocarcinoma of the endometrium of any FIGO grade 168 
without evidence of extra-uterine disease by imaging (computed tomography (CT) or Magnetic 169 
Resonance Imaging (MRI) of the abdomen and pelvis and chest radiograph or chest CT). Women 170 
with a histological cell-type other than endometrioid on curettage, clinically advanced disease 171 
(stage II – IV using FIGO 2009 criteria for stage or bulky lymph nodes on imaging), uterine size 172 
greater than 10 weeks of gestation were ineligible.  173 
Patient-related assessments were collected prior to surgery, and at week 1, and months 1, 3, and 174 
6, post-surgery. All patients were followed at 12 months, and then annually for survival outcomes. 175 
Patients without events were censored at the date of data lock (3rd March 2016) or date of last 176 
contact for patients lost to follow up.  177 
Verification of surgery, histopathology and baseline eligibility assessment documents was 178 
conducted for all patients. Presence of recurrent disease was confirmed histologically whenever 179 
feasible. 180 
There were two phases in the study design. In the event that the study would not be able to 181 
proceed to the clinical endpoint of DFS, a 2:1 allocation TLH:TAH for the first 150 patients was 182 
performed to gain key information on the effect of the intervention on QoL. Thereafter patients 183 
were randomized to TAH or TLH by mixed permuted blocks of size 3 and 6 using computer-184 
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generated random number sequences. Randomization was performed centrally (School of 185 
Population Health, University of Queensland) to ensure allocation concealment. The first phase of 186 
the trial focused on QoL. Randomization for the remainder of the study to evaluate clinical 187 
outcomes commenced with a ratio of 1:0.76 ratio to re-balance the treatment allocation. This 188 
however did not prove to be practical and the allocation ratio was changed to 1:1. Due to the 2:1 189 
allocation of the first 150 patients, it was expected that about 55 more patients would be allocated to 190 
TLH compared to TAH at the end of the trial. Randomization was stratified by treating centre, 191 
grade of differentiation and history of cancer (second phase only). Blinding of treatment allocation 192 
was impractical in this setting (see online supplement trial protocol page 17 for details about 193 
allocation and stratification). 194 
 The surgical procedures and their steps have been described in detail previously.
15
 Prior to 195 
surgery, all patients had to have a complete physical examination, imaging as described above, an 196 
Electrocardiogram and routine blood tests (clinical chemistry, haematology). For the TLH an 197 
anatomically curved silicone tube with a proximal airtight cap that prevents loss of 198 
pneumoperitoneum, enables instrument access and facilitates the safe removal of specimens 199 
transvaginally was used (McCartney Tube
TM
, The O.R. Company, Melbourne, Australia). TAH was 200 
performed through a vertical midline or lower transverse incision.  201 
Surgeons were required to perform pelvic (with or without para-aortic) lymph-node dissection as 202 
part of the treatment in both groups. A lymph-node dissection could only be omitted if one of the 203 
following criteria were met: morbid obesity, Grade 1 (well-differentiated) or Grade 2 (moderately-204 
differentiated) without myometrial invasion or with a depth of invasion of less than the inner half of 205 
the myometrium based on frozen section, or the patient was medically unfit for lymph-node 206 
dissection, or institutional guidelines advising against the lymphadenectomy. Morcellation was not 207 
allowed.  208 
Histopathological findings were used to determine the need for adjuvant treatment according to 209 
local institutional clinical practice guidelines, and typically were discussed in multidisciplinary 210 
meetings. The delivery and management of radiation therapy or chemotherapy was carried out 211 
according to local institutional clinical practice guidelines. Data on dosimetry or chemotherapy 212 
dosing was recorded. 213 
All clinical Adverse Events (AEs) encountered during the clinical study were documented. The 214 
intensity of AEs was graded using the National Cancer Institute Common Terminology Criteria for 215 
Adverse Events version 3.0 (CTC-AE v3.0). The incidence of, and risk factors for, AEs was 216 
reported previously.
16, 17
  217 
 218 
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For quality assurance, a rigorous accreditation process was followed as described in detail 219 
previously.
15
 Surgeons were required to (i) be certified gynecological oncologists proficient in TAH 220 
or under the direct supervision of a certified gynecological oncologist in theatre; and (ii) provide 221 
evidence of a minimal number of 20 supervised and documented TLHs performed as the main 222 
surgeon; and (iii) have submitted an unedited video of a TLH for assessment by the trial credential 223 
committee. Finally, all prospective surgeons had to perform a live TLH for endometrial cancer 224 
evaluated by one of the LACE accredited surgeons prior to their own accreditation.  225 
The specific requirements for a surgeon to participate on the trial were: 1. Able to secure uterine 226 
vessels at the level of the uterus laparoscopically; 2. Able to perform a laparoscopic retroperitoneal 227 
node dissection (pelvic); 3. Able to suture vaginal vault laparoscopically. These surgical steps were 228 
checked at accreditation of every trial surgeon. Given that all participating surgeons were certified 229 
gynecological oncologists and given that there are variations how those tasks could be achieved, no 230 
further standardisation of surgical technique was attempted.  231 
 232 
Patients were seen for follow-up every three months after surgery for the first two years and 233 
every six months until their postsurgical year five. Clinical assessments including gynecological 234 
examinations were performed at each visit.  Routine medical imaging of asymptomatic women was 235 
not performed.
18, 19
 However, medical imaging was performed to evaluate patients with symptoms 236 
that are consistent with recurrence.  237 
Imaging was performed if there was a patient complaint or clinical finding justifying such 238 
procedure. Clinical assessment, radiological work-up  histological confirmation of recurrence 239 
proved the presence of recurrent disease. As per protocol, the presence of a recurrence had to be 240 
biopsy proven whenever possible. However in exceptional circumstances, where it would have been 241 
ethically not justifiable to take a biopsy and if clinical and/or radiological and tumour marker 242 
evidence was overwhelming we relied on clinical findings.  243 
The independent Data and Safety Monitoring Committee (IDSMC) included two gynecological 244 
oncologists who were not otherwise involved in this trial, a medical oncologist and a biostatistician. 245 
The IDSMC met biannually and monitored patient safety and toxicity data, serious AEs and 246 
mortality. 247 
Outcomes 248 
The primary outcome was DFS, which was measured as the time interval between surgery and date 249 
of first recurrence, including disease progression or the development of a new primary cancer or 250 
death. Patients who were disease free at the end of the study were censored at their last follow up 251 
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visit. Patients developing new primary tumours during the course of the study would move to a 252 
different risk profile compared with those not developing a new primary. As this was a pragmatic 253 
study, to account for this risk, DFS was defined to include the development of new primary 254 
disease.
20
 Similarly death (from any cause) was also considered as an event.  255 
Prespecified secondary outcomes reported here included recurrence, patterns of recurrence, and 256 
overall survival (OS). Prespecified secondary outcomes not reported here, but previously reported 257 
elsewhere are morbidity, pain, analgesic consumption, QoL, and cost-effectiveness.
7,16, 17, 21, 22
 In 258 
early recovery (up to 4 weeks after surgery), patients treated with TLH compared to TAH had a 259 
13% and 11% greater improvement in their functional and physical well-being, respectively. 260 
Smaller QoL benefits for TLH persisted into the late recovery phase 3–6 months after surgery. 7 261 
While intraoperative adverse events were similar between the two groups, postoperative adverse 262 
events were less frequent in patients after TLH compared to TAH. 
17
 Costs were lower for TLH.
11
 263 
  264 
Statistical Analysis 265 
The statistical design and sample size calculations were based on a 4·5-year DFS rate of 90% in the 266 
TAH arm,
3
 and a 7% margin at 4·5 years. This corresponded to a DFS rate of 83%, and was deemed 267 
to be sufficiently small to declare TLH to be equivalent to TAH. A sample size of 755 patients 268 
would be sufficient to declare TLH equivalent to TAH with 90% power and a pre-specified margin, 269 
∆= ±7%, based on 5 years of patient accrual and 4·5 years of follow-up. An equivalence margin of 270 
7% or less was determined to be clinically acceptable, as established in this and other disease 271 
sites.
23-25
 272 
Equivalence would be declared if both the lower and upper bounds of the 95% confidence interval 273 
(CI) for difference in the DFS rates between surgical groups at 4·5-years post-randomization were 274 
not greater than ∆= ±7%. A p value of <0.05 rejects the null hypothesis, and confirms equivalence. 275 
All statistical analyses were conducted according to the intention-to-treat (ITT) principle. 276 
Additional exploratory analyses according to per-protocol (excluding patients that did not receive 277 
their randomized treatment allocation) and by the surgery patients actually received was performed. 278 
Treatment comparisons of continuous data were performed using t-tests and categorical variables 279 
using chi-square tests. DFS rates at 4·5-years were estimated using the method of Kaplan-Meier.
16
 280 
Hazard ratios for DFS and OS in bivariate and multivariable models were obtained using 281 
proportional hazards models.  282 
Exploratory multivariable analyses for DFS and OS was performed adjusting for pre-specified 283 
prognostic factors including treatment type, age, BMI, FIGO surgical stage, grade of differentiation, 284 
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lymph node involvement, history of malignancy and ECOG status. Subgroup analyses were 285 
performed according to stratification variables and other pre-specified clinically relevant groups, 286 
with tests for interaction by logistic regression in which the outcome was DFS at 4.5-years (yes vs 287 
no). 288 
All analyses were performed at the 5% level of significance (two-sided) and conducted in SAS 289 
version 9.3 (SAS Institute, Inc, Cary, NC) and STATA version 14.1 (Statacorp, Texas). No 290 
statistical adjustments to the analysis were made for multiple testing or to account for missing data. 291 
Results 292 
Study Population and Assigned Treatment 293 
760 patients were randomized to TAH (n=353) or TLH (n=407) (Figure 1). A total of 27 surgeons 294 
were accredited and enrolled patients into the trial. The median follow-up time was 4.5 years. The 295 
two groups were well balanced across stratification and other baseline factors (Table 1). Medical 296 
comorbidities were equally distributed across both surgical arms. There were no statistical 297 
differences in the types of tumour between the two groups, with the majority being endometrioid 298 
adenocarcinomas (97%). There were no significant differences between the groups in FIGO 299 
surgical staging, histological grade, number of metastatic lymph nodes or adjuvant treatment (Table 300 
2). 301 
Twenty-seven (7%) of patients randomized to TLH did not receive the assigned surgical procedure, 302 
twenty-four (6%) being converted from laparoscopy to laparotomy (15 for anatomical reasons 303 
(incision to remove the uterus; uterus too large, vagina too narrow etc.), 7 due to complications and 304 
2 for technical reasons). In the remaining 3 patients that did not undergo a TLH, 2 withdrew prior to 305 
surgery and 1 patient had their surgery abandoned due to clinically advanced disease with vaginal 306 
involvement that was unrecognized until the day of surgery (Figure 1). Similarly, five (2%) patients 307 
randomized to TAH received TLH due to refusal of TAH and two patients withdrew prior to 308 
surgery. There were 81 (11%) patients lost to follow up by 4.5 years; baseline characteristics did not 309 
differ in these patients compared to those who completed follow-up (Supplementary Table 1). All 310 
patients were included in their randomized treatment group for ITT analysis.  311 
Disease-free survival 312 
In the ITT analysis of the primary outcome, 60 (17.0%) of patients who had been assigned to TAH, 313 
and 70 (17.2%) of patients assigned to TLH experienced an event by 4.5 years post-randomization. 314 
Based on the Kaplan-Meier estimates, the probability of DFS at 4.5 years was 81.3% in the TAH 315 
group and 81.6% in the TLH group with a DFS difference of 0.3% (95% CI: -5.53% to 6.13) 316 
favouring TLH. Both the lower and upper boundary of the two-sided 95% confidence interval 317 
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excluded the pre-specified equivalence margin of ∆= ±7% (p for equivalence=0.007), supporting 318 
the conclusion that TLH is equivalent to TAH. Supporting per-protocol (PP) analyses revealed the 319 
probability of not having a DFS event as 81.4% (346 patients) in the TAH group vs 83.0% (381 320 
patients) in the TLH group at 4.5 years giving a difference of 1.6% (95% CI: -4.3% to 7.5%) in 321 
favour of TLH. For the treatment-received groups the DFS rates were 80.0% in TAH group vs 322 
82.9% in TLH group giving a difference of 2.9% (95% CI: -2.9% to 8.7%). 323 
Secondary outcomes: 324 
There was no statistical difference in DFS between patients assigned to TAH or TLH over the study 325 
period (HR 1.03 95% CI 0.73 to 1.44; p=0.87) (Figure 2a), or in the primary site of recurrence, 326 
with 12 (3%) patients in the TAH group and 14 (3%) in the TLH group relapsing at the vaginal 327 
vault, and 2% or less of patients experiencing a relapse in the pelvis, abdomen, at distant organs or 328 
multiple sites in both groups (Table 3). A post-hoc sensitivity analysis of DFS excluding the new 329 
primary cancers and deaths found a difference of -0.02% (95% CI: -4.22% to 4.18) from Kaplan-330 
Meier estimates (Supplementary Figure 1). 331 
There were two patients with port-site metastases in the TLH group and both patients presented 332 
with multiple peritoneal metastases including at the port site(s). Similarly, two patients in the TAH 333 
group developed recurrences at the site of the abdominal wound. One of these patients presented 334 
with multiple metastases including liver and lung and another patient had an isolated recurrence at 335 
the vertical midline scar.  336 
In total, 24 (6.8%) patients in the TAH group and 30 (7.4%) in the TLH group died, with an 337 
estimated 4.5-year OS rate (based on Kaplan-Meier estimates) of 92.4% vs 92.0% respectively 338 
(survival difference: -0.34%, 95% CI -4.4 to 3.7). There was no significant difference in OS 339 
between the two groups (HR 1.08 95% CI 0.63 to 1.85; p=0.78) (Figure 2b). The cause of death 340 
was balanced across the treatment groups with the majority of deaths (56%) due to endometrial 341 
cancer (Table 3). Prognostic factors associated with DFS and OS are given in Supplementary 342 
Table 2 and include history of malignancy, increasing age and higher surgical stage and stage of 343 
differentiation but not randomized treatment. 344 
Prognostic factors for disease-free survival 345 
Exploratory analyses for differences in rates of DFS between the pre-specified prognostic 346 
subgroups are presented in Supplementary Figure 2. A significant interaction (P=0·038) for BMI 347 
(<30 vs ≥ 30) was found, in which patients with lower BMI had higher rates of DFS in the TAH 348 
group compared to TLH (86·6% vs 77·4%), whereas the TLH group had higher DFS rates at 4.5 349 
years for patients with BMI ≥ 30 (78·9% vs 84·4%). There were no statistically significant 350 
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differences between TAH and TLH in any of the other subgroups, including age (<65 vs ≥ 65 351 
years), FIGO staging (1 vs >1), ECOG (0 vs 1), Charlson index (<3 vs ≥ 3) or history of 352 
malignancy (yes vs no). 353 
A multivariable analysis using proportional hazard regression of DFS adjusting for pre-specified 354 
prognostic factors did not materially change the treatment effect (Supplementary Table 2). The 355 
unadjusted hazard ratio (HR) was 1·03 [95% CI: 0·74 to 1·45, P=0·85] compared to an adjusted HR 356 
of 1·02 [95% CI: 0·68 to 1·52, P=0·94]. 357 
Discussion 358 
In this clinical trial of 760 women with stage I endometrial cancer, DFS at 4.5 years was 81.6% 359 
with total laparoscopic hysterectomy compared to 81.3% with total abdominal hysterectomy 360 
(difference 0.3%, 95% CI, -5.5% to 6.13%) meeting criteria for equivalence. Although a limited 361 
number of clinical trials have attempted to address the performance and safety of these two 362 
modalities, the current trial represents the first multi-centre, international trial where all surgeons 363 
were tasked to perform the hysterectomy totally laparoscopically. Surgeon screening procedures 364 
were done to achieve a high standard of surgery and this was reflected in a low conversion rate, and 365 
a high DFS rate. The incidence of post-operative wound metastases was of low incidence 366 
(0.0047%) and no different in frequency between the arms. The results reported here are robust 367 
across survival rates and hazard ratios, intention-to-treat and as-treated analyses, DFS and 368 
endometrial cancer  specific-recurrence free survival, and the 4.5-year time point is sufficiently long 369 
to capture any separation in the survival curves.
26
 The apparent DFS benefit of TLH in women with 370 
BMI ≥ 30 is counter-intuitive but as the CI’s for estimates in the individual subgroups overlap this 371 
may well be a statistical artefact. Laparoscopic surgery has benefits for patients with regards to 372 
QoL, recovery after surgery, hospital stay and adverse events.
12
 Given its better short-term 373 
outcomes, updated meta-analyses should now be conducted to determine whether TLH should 374 
become the standard of care for the majority of patients with stage 1 endometrial cancer. 375 
Published reports from trials have been summarised in a Cochrane meta-analysis.
12
 Until now, the 376 
only randomized evidence assessing long-term survival outcomes from a sufficiently powered and 377 
multicentre trial was the U.S. LAP2 Trial (GOG 222). LAP2 recruited a total of 2,616 women and 378 
formally failed to meet the criteria for noninferiority based on a HR boundary of 1·4,
25
 potentially 379 
due to the smaller than expected rate of recurrences. There were some important differences 380 
between the trial reported here and the LAP2 trial. LAP2 trial enrolled patients with all cell types, 381 
whereas the present trial focused on endometrioid cell type on preoperative uterine curettings. All 382 
patients enrolled into LAP2 had to have a retroperitoneal node dissection, including para-aortic 383 
nodes. It has been argued that the high conversion rate from laparoscopy to laparotomy (25·8% in 384 
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LAP2, compared to only 6% in this trial) was due to that requirement.
27
 Only half of all patients 385 
enrolled in this trial received a retroperitoneal node dissection and patients who received TLH were 386 
less likely to have a node dissection. This reflects the existing, wide variation in opinions about the 387 
need of comprehensive surgical staging and lymphadenectomy.
2
   388 
Previously reported adverse event results of this trial,
16, 17
 confirmed LAP2 trial results
10
 and the 389 
results from other studies summarised in the Cochrane review.
12
 Intraoperative surgical 390 
complications were comparable between patients assigned to TAH and TLH in the three large trials 391 
conducted worldwide to date.
9, 10, 17
 In regards to postoperative surgical adverse events, the Dutch 392 
trial 
9
 recorded similar postoperative surgical complications in the abdominal and the laparoscopic 393 
group, whereas LH led to fewer postoperative surgical complications in LAP2
10
 and the present 394 
trial.
17
 QOL outcomes favoured TLH over TAH in all three of these trials. The present analyses 395 
now showed that endometrial cancer patients treated by TLH had equivalent survival outcomes up 396 
to 4.5 years after surgery. Others reported that long-term survival outcomes of patients are also 397 
promising for TLH. 
28
 398 
Limitations of this trial include that blinding of patients or surgeons was not undertaken, however it 399 
is unlikely to affect the DFS or OS outcomes reported here, which were collected independently 400 
from the treating surgeons by dedicated clinical trial staff. Furthermore, randomization was not 401 
deferred until the patient entered the operating room, due to the different set-up required for the 402 
surgical procedures. Due to funding constraints, the trial followed a pragmatic 2-phase design,
29
 403 
first focussing on QOL initially, then on DFS and OS once the recruitment of a sufficiently large 404 
number of patients was supported by the funders of this trial.  In this trial the matter of pelvic and 405 
aortic retroperitoneal node dissection followed the current clinical practice guidelines of the 406 
participating surgeons and institutions.  407 
Conclusions 408 
Among women with stage I endometrioid endometrial cancer, the use of TAH compared with TLH 409 
resulted in equivalent DFS at 4.5 years. These findings support the use of laparoscopic 410 
hysterectomy for stage 1 endometrial cancer. The results come from a multinational trial boosting 411 
confidence that a consistent high quality surgery result can be achieved within different hospitals 412 
and healthcare systems. Given the well documented and wide-ranging health benefits of 413 
laparoscopic hysterectomy compared to TAH, 
12, 30
 and the absence of increased adverse events, 414 
TLH should become widely used in the surgical treatment of early stage endometrial cancer. New 415 
and emerging surgical methods of treating early stage endometrial cancer should now be tested 416 
against TLH in the future with regards to QOL, safety, AEs, pain, cost and survival outcomes. 417 
418 
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Figure captions:  444 
Figure 1: Consort flow diagram of the LACE trial  445 
a
 The trial proceeded in two phases. During the first phase that focussed on quality of life outcomes, 446 
randomization was 2:1 TLH:TAH. After that, randomization for the second phase, started with a 447 
1:0.76 ratio in an attempt to re-balance sample sizes between the two arms, but when this proved 448 
unworkable in the field, the allocation ratio was changed to 1:1. 449 
b
1 patient withdrew as unable to return for follow-up visits, 1 patient withdrew as did not want to 450 
remain on study 451 
c
2 patients withdrew  452 
d
Surgery abandoned due to clinically advanced disease with vaginal involvement 453 
e 
Reasons for not meeting the inclusion criteria:
 
Histology not confirmed diagnosis of primary 454 
endometriod adenocarcinoma of the endometrium n=12; Performance status of ECOG >1 n=20; 455 
Age less than 18 = 0; Other histologic type than endometriod adenocarcinoma of the endometrium 456 
n=164; Clinically advanced disease (stages II-IV) n=150; Uterine size larger than 10 week gestation 457 
n=78; Estimated life expectancy of less than 6 months n=0; Enlarged aortic lymph nodes n=11; 458 
Serious concomitant systemic disorders incompatible with the study n=134; Patient compliance and 459 
geographic proximity do not allow for adequate follow-up n=30; Patient unfit to complete QoL 460 
measurements n=49. 461 
 462 
Figure 2a: Cumulative incidence of recurrence or death by surgical group 463 
 464 
Figure 2b: Cumulative incidence of death by surgical group 465 
 466 
 467 
  468 
469 
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 470 
Table 1: Baseline Characteristics of the intention-to-treat population 
  Total Laparoscopic 
Hysterectomy 
(N=407) 
Total Abdominal 
Hysterectomy 
(N=353) 
Age at randomization (Years)  Mean(SD) 63.3 (10.0) 63.1 (10.6) 
 <65 231 (57%) 198 (56%) 
 ≥65 174 (43%) 157 (44%) 
BMI, N(%) Median(range) 33.1 (18.8 to 63.3) 32.7 (19.1 to 63.2) 
 <30 143 (35%) 119 (34%) 
 ≥30 244 (60%) 222 (63%) 
Grade of differentiation upon Dilation 
& Curette, N(%) 
Grade 1 259 (64%) 223 (63%) 
 Grade 2 120 (29%) 107 (30%) 
 Grade 3 28 (7%) 23 (7%) 
Any malignancy a, N(%)  28 (9%) 20 (7%) 
Charlson Indexb, N(%) Median(range) 3 (0 to 10) 3 (0 to 8) 
 <3 171 (42%) 159 (45%) 
 ≥3 230 (57%) 196 (55%) 
Ongoing Medicationc, N(%)  332 (82%) 273 (77%) 
ECOG Performance Statusd, N(%) 0 352 (86%) 303 (86%) 
 1 55 (14%) 50 (14%) 
    
Data are n (%), Mean (SD) or Median (range). Abbreviations: BMI = body-mass index; ECOG = 
Eastern Cooperative Oncology Group.   a Refers to any malignancy prior to the index malignancy. 
Numbers are based on TAH=303 and TLH=306 due to the different stratification schemes between 
Phase 1 and Phase 2 b The Charlson index summarises the patient’s comorbidity burden, with higher 
scores indicating greater burden c Ongoing medications are those without an end-date during trial 
participation noted, indicating comorbidity burden d ECOG- Performance scale (range of scores 0 - 
perfect health to  5 - death) 
 
472 
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 473 
  Table 2:  Surgery and Adjuvant Treatment Details  
  
Total Laparoscopic 
Hysterectomy 
(N=407) 
Total Abdominal 
Hysterectomy 
(N=353) 
Risk Difference, % 
(95% CI) 
p-value 
Surgical and Pathological 
Outcomes    
  
Days to surgery (from 
randomization), Median (range) 
 7 (0 to 62) 7 (0 to 74)  0.70 
Duration of operation (minutes), 
Median (range) 
 130 (50 to 300) 105 (35 to 249)  <0.001 
Change in haemoglobin levels 
from baseline to one week post-
surgery (g/dl), Median (range) 
 -17 (-55 to 15) -19 (-111 to 31)  0.14 
Pelvic/Aortic Lymph Node 
Dissection, N(%) 
 161 (40%) 206 (58%) -18.8 (-25.8 to -11.8) <0.001 
FIGO Surgical Stage
 a, N(%) IA 286 (70%) 237 (67%) 3.1 (-3.5 to 9.7) 0.27 
 IB 55 (14%) 44 (13%) 1.0 (-3.7 to 5.8)   
 II 32 (8%) 45 (13%) -4.9 (-9.2 to -0.5)  
 IIIA 11 (3%) 4 (1%) 1.6 (-0.4 to 3.5)  
 IIIB 4 (1%) 1 (<1%) 0.7 (-0.4 to 1.8)  
 IIIC1 11 (3%) 12 (3%) -0.7 (-3.2 to 1.7)  
 IIIC2 1 (<1%) 3 (1%) -0.6 (-1.7 to 0.5)  
 IIIIA 0 (<1%) 1 (<1%) -0.3 (-0.8 to 0.3)  
 IIIIB 3 (1%) 3 (1%) -0.1 (-1.4 to 1.2)  
 Unknown 4 (1%) 3 (1%) 0.1 (-1.2 to 1.5)  
      
Cell type, N(%)      
Endometrioid   395 (97%) 340 (96%) 0.7 (-1.8 to 3.3)  
Clear cell  4 (1%) 7 (2%) -1.0 (-2.7 to 0.7)  
Adenocarcinoma  1 (<1%) 5 (1%) -1.2 (-2.5 to 0.2)  
Mixed Epithelial  0 (0%) 3 (1%) -0.8 (-1.8 to 0.1)  
Sarcoma  2 (<1%) 1 (<1%) 0.2 (-0.7 to 1.0)  
Serous  7 (2%) 12 (3%) -1.7 (-4.0 to 0.6)   
Mucinous  7 (2%) 2 (1%) 1.1 (-0.3 to 2.6)  
Small cell  2 (<1%) 0 (0%) 0.5 (-0.2 to 1.2)  
FIGO Grade
b, N(%) 1 231 (57%) 185 (52%) 4.3 (-2.7 10 11.4) 0.27 
 2 129 (32%) 124 (35%) -3.5 (-10.2 to 3.3)  
 3 43 (11%) 40 (11%) -0.8 (-5.2 to 3.7)  
 Unknown 4 (1%) 4 (1%) -0.2 (-1.6 to 1.3)  
Number of lymph nodes 
examined 
Median (range) 11 (7 to 15) 10 (5 to 28)  0.88 
 20 
Number of metastatic lymph 
nodes 
Median (range) 0 (0 to 2) 0 (0 to 1)  0.84 
      
Adjuvant Treatment, N(%) Chemotherapy 
Only 
8 (2%) 7 (2%) -0.01 (-2.0 to 2.0) 0.99 
 Radiation 
Treatment  Only 
61 (15%) 66 (19%) -3.7 (-9.1 to 1.6) 0.17 
 Both 
Chemotherapy and 
Radiation 
Treatment  
22 (5%) 19 (5%) 0.02 (-3.2 to 3.2) 0.99 
a
 International Federation of Gynecology and Obstetrics (FIGO) surgical stage: Stage Ia Tumor limited to the 474 
endometrium; Stage Ib Invasion to less than half of the myometrium 475 
Stage Ic Invasion equal to or more than half of the myometrium; Stage IIa Endocervical glandular involvement only; 476 
Stage IIb Cervical stromal invasion; Stage IIIa Tumor invades the serosa of the corpus uteri and/or adnexae and/or 477 
positive cytological findings; Stage IIIb Vaginal metastases b Figo grade: G1: Well differentiated; G2: Moderately 478 
differentiated; G3: Poorly or undifferentiated 479 
 480 
 481 
482 
 21 
 483 
Table 3: Survival Outcomes     
 
  Total Laparoscopic 
Hysterectomy 
(N=407) 
Total Abdominal 
Hysterectomy 
(N=353) 
 
Risk Difference, 
% (95% CI) 
p-value 
Survival Outcomes      
Probability of DFS at 4.5 years  81.6% 81.3%   
Difference in TAH and TLH based 
on equivalence boundary of 
∆=±7% 
 0.3% (-5.53% to 6.13)  0.007* 
Recurrences or deathsa, N(%)  
 70 (17%) 60 (17%) 0.2 (-5.1 to 5.6) 0.54 
Recurrences alonea,b, N(%) 
 
 33 (8%) 28 (8%) 0.2 (-3.7 to 4.0) 0.93 
Primary site of relapse Vault 14 (3%) 12 (3%) 0.04 (-2.5 to 2.6) 0.98 
 Pelvis 2 (<1%) 4 (1%) -0.6 (-1.9 to 0.7) 0.32 
 Abdomen 6 (1%) 6 (2%) -0.2 (-2.0 to 1.6) 0.84 
 Distant 5 (1%) 4 (1%) 0.1 (-1.4 to 1.6) 0.90 
 Multiple 6 (1%) 2 (1%) 0.9 (-0.5 to 2.3) 0.22 
      
New primary cancer Any type 37 (9%) 27 (8%) 1.4 (-2.5 to 5.4) 0.48 
 Breast 7 10   
 Colorectal 3 5   
 Skin 19 9   
 Haematological 4 1   
 Lung 3 1   
 Pancreatic 1 0   
 Thyroid 0 1   
               Other     
Deathsc  30 (7%) 24 (7%) 0.6 (-3.0 to 4.2) 0.76 
Cause of Death Endometrial Cancer 16 (4%) 14 (4%)  -0.03 (-2.8 to 2.7) 0.98 
 Unrelated Morbidity 5 (1%) 2 (1%) 0.7 (-0.6 to 2.0)  
 Unknown 9 (2%) 8 (2%) -0.05 (-2.2 to 2.1)  
Abbreviations: DFS = disease-free survival *P-value for equivalence testing the null-hypothesis that the two groups are 484 
different by at least 7%. A p value of 0.007 rejects the null hypothesis, and confirms equivalence. 485 
aAny event that occurred between randomization and 4.5-years post-randomization 486 
b Definition excludes deaths and new primary cancers 487 
cAny event that occurred between randomization and data lock (3rd March 2016) 488 
489 
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